Aug. 23, 2021 FDA Grants Full Approval to the Pfizer-BioNTech COVID-19 Vaccine:

On August 23, 2021, the U.S. Food and Drug Administration (FDA) announced that the agency has granted full approval to the Pfizer-BioNTech COVID-19 vaccine for adults sixteen years of age and older. This vaccine is the first COVID-19 vaccine to be fully approved by the FDA and it will be labeled and marketed as “Comirnaty.” While the agency’s full approval of Comirnaty applies to adults, the use of the vaccine by individuals between the ages of twelve and fifteen remains subject to the FDA’s Emergency Use Authorization (EUA) and is not yet available to children under the age of twelve. In addition to granting approval for Comirnaty, the FDA is requiring Pfizer-BioNTech to conduct ongoing safety monitoring of the product to study the risk of individuals developing myocarditis and pericarditis following vaccination, including collecting data on long-term health outcomes of individuals who develop myocarditis following vaccination. On their own initiative, Pfizer-BioNTech have committed to conduct a pregnancy registry study to assess the health outcomes of pregnant women and infants following vaccination with Comirnaty during pregnancy.

The vaccines offered by Moderna and Johnson & Johnson are both still subject to their original EUA and not yet fully approved by the FDA. However, the original Emergency Use Authorizations for these vaccines were granted after the EUA for the Pfizer-BioNTech vaccine, which suggests that full approval for these vaccines will be granted soon.

FDA Authorizes First Vaccine Booster for Children 5-11

On May 17, 2022, the U.S. Food and Drug Administration (FDA) amended the Emergency Use Authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine (marketed as Comirnaty) to authorize the use of a single booster dose for children between the ages of five and eleven. The FDA authorized the administration of this booster at least five months after the completion of the primary vaccination series with the same vaccine.

Continue Reading...

R.T. Asked: When Can I Get the COVID-19 Booster After Receiving Monoclonal Antibodies?

“When should immunocompromised patients get their second COVID-19 vaccine booster after receiving monoclonal antibodies? We are getting conflicting information from doctors, the news, medical literature, and hospitals on whether it is safe to receive a COVID-19 vaccine or vaccine booster after receiving monoclonal antibodies and whether doing this will reduce the efficacy of the vaccine. We are in a quandary, not knowing what to do.”

Continue Reading...

Pandemic Patients is a 501(c)(3) non-profit organization that works to relieve the harm caused by COVID-19 and post-COVID conditions. EIN 86-3930257.

Please consider making a charitable donation to help us advance our important work.

Prior to using this website, please review our Terms of Use and Privacy Policy.